Our round-up of biotech financings is led this week by Braveheart Bio, a San Francisco biotech that has launched with $185 million, a lead drug for hypertrophic cardiomyopathy (HCM), and Biogen CEO ...
A clinical-stage cardiovascular biotech developing BHB-1893, a next-generation oral cardiac myosin inhibitor targeting hypertrophic cardiomyopathy, with Phase III trials imminent and a Nasdaq IPO set ...
‘Braveheart’ is packed with sweeping battles and memorable images, but a lot of what you see on screen does not match the real history. Many choices were made to heighten drama and simplify events for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results